Malaria is caused by the transmission of parasites belonging to genus plasmodium. These parasites are transmitted through the bite of female Anopheles mosquito, which then get lodged into liver. These parasites grow in liver and multiply to further invade the red blood cells where these parasites mature and rupture the blood cell to form merozoites. These merozoites then invade other red blood cells, causing symptoms such as high fever, fatigue, dizziness, and others. Thus, malaria is highly fatal if left untreated for a long period of time. Therefore, the drugs used in the treatment of malaria are called as antimalarial drugs. Furthermore, there are different types of antimalarial drugs available in the market, which include quinine, chloroquine, proguanil, mefloquine, pyrimethamine, and others. In addition, these drugs can be purchased on prescription from different type of pharmacies such as hospital and retail pharmacies. Moreover, these drugs are also available on e-commerce websites.
The major factor that drives the growth of the antimalarial drugs market include rise in The prevalence of malaria in developing countries. Furthermore, rise in awareness initiatives by governments and surge in research for new antimalarial drugs are some of the factors that boost the growth of the market. However, lack of awareness regarding healthcare in developing countries is a major factor that restrains the growth of the antimalarial drugs market. Conversely, growth opportunities exhibited by emerging economies are expected to offer lucrative opportunities for the market expansion during the forecast period.
The antimalarial drugs market size is studied on the basis of drug class, distribution channel, and region to provide a detailed assessment of the market. On the basis of drug class, it is segmented into quinine, chloroquine, proguanil, mefloquine, pyrimethamine, and others. By distribution channel, it is divided into hospital pharmacy, retail pharmacy, and e-commerce & other distribution channel. Region wise, it is analyzed across North America (the U.S. and Canada), Europe (Germany, the UK, and rest of Europe), Asia-Pacific (China, India, and rest of Asia-Pacific), and LAMEA (Africa and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
- This report entails a detailed quantitative analysis along with the current global antimalarial drugsmarket trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessments.
- The market size and estimations are based on a comprehensive analysis of key developments in the industry.
- A qualitative analysis based on innovative products facilitates strategic business planning.
- The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
Key Market Segments
By Drug Class
- Quinine
- Chloroquine
- Proguanil
- Mefloquine
- Pyrimethamine
- Others
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- E-Commerce & Other Distribution Channel
By Region
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- Rest of Europe
- Asia-Pacific
- China
- India
- Rest of Asia-Pacific
- LAMEA
- Africa
- Rest of LAMEA
List of key players profiled in the report:
- Alvizia Healthcare Pvt. Ltd.
- Bayer AG
- F. Hoffmann-La Roche Ltd
- GlaxoSmithKline plc
- Ipca Laboratories Ltd.
- Merck & Co., Inc
- Novartis AG
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd. (Ranbaxy Laboratories)
- Zydus Cadila
LIST OF OTHER PLAYERS IN THE VALUE CHAIN(These players are not profiled in the report. The same will be included on request)
- Cipla Limited
- Ajanta Pharma
Table of Contents
Executive Summary
According to this report titled, 'Antimalarial Drugs Market by Drug Class and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2018-2026,' the global antimalarial drugs market was valued at $711,360 thous and in 2018, and is expected to reach $1,019,396 thous and by 2026, registering a CAGR of 4.6% from 2019 to 2026.Malaria is a deadly infectious disease, which is transmitted through the bite of female Anopheles mosquito. The infection spreads to liver cells where the parasites multiply at a fast rate to invade red blood cells. These parasites further grow and mature in red blood cells to form merozoites, which are released upon the rupture of red blood cells to invade other blood cells. This leads to fever, tiredness, vomiting, headaches, impaired consciousness, multiple convulsions, and abnormal bleeding. Hence, the drugs which are employed in the treatment of malarial infection are called as antimalarial drugs. There are different types of antimalarial drugs such as quinine, chloroquine, proguanil, mefloquine, pyrimethamine, and others available in the market.
The major factor that drives the growth of the antimalarial drugs market include rise in The prevalence of malaria in developing countries. Furthermore, rise in awareness initiatives by governments and surge in research for new antimalarial drugs are some of the factors that boost the growth of the market. However, lack of awareness about healthcare in developing countries is a major factor that restricts the growth of the antimalarial drugs market in the region. Conversely, growth opportunities exhibited by emerging economies are expected to offer lucrative opportunities during the forecast period.
The antimalarial drugs market size is studied on the basis of drug class, distribution channel, and region to provide a detailed assessment of the market. On the basis of drug class, it is segmented into quinine, chloroquine, proguanil, mefloquine, pyrimethamine, and others. By distribution channel, it is bifurcated into hospital pharmacy, retail pharmacy, and e-commerce & other distribution channel. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, and rest of Europe), Asia-Pacific (China, Japan, India, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).
According to drug class, the others segment occupied the major share of the antimalarial drugs market. Furthermore, the segment is also expected to exhibit the fastest growth rate during the forecast period, owing to the factor that malaria parasites have successfully developed resistance against most of the drugs already available in the market.
By distribution channel, the hospital pharmacy segment acquired the major share due to a rise in the number of hospitals worldwide. Furthermore, antimalarial drugs are prescription-based medications, which are mostly prescribed by the specialized healthcare professionals available in hospitals; thereby, propelling the growth of this segment. Conversely, the e-commerce segment is expected to exhibit the fastest growth rate during the forecast period, owing to surge in the use of internet across the globe.
By region, North America accounted for the major antimalarial drugs market share in 2018 and is expected to continue this trend, owing to easy availability of antimalarial drugs. Moreover, surge in incidence of malaria is another major reason that contributes to the growth of this market. On the other side, Asia-Pacific is estimated to register the fastest growth during the forecast period due to increase in awareness regarding the use of antimalarial drugs. Furthermore, constantly evolving life science industry drives the growth of the market in developing economies such as India, China, and Malaysia. As the constant development leads to surge in awareness related to the use of antimalarial drugs. In addition, it also leads to rise in aesthetic consciousness among people; which further fuels the growth of the market.
According to Onkar Sumant, Manager, Healthcare, “The demand for antimalarial drugs is on rise, owing to surge in malaria across the globe. Furthermore, rise in awareness initiatives by government is another major factor that contributes to the growth of this market.”
KEY FINDINGS OF THE STUDY
- Quinine check occupied approximately one-fourth share of the global antimalarial drugsmarket in 2018.
- The others segment in drug class is anticipated to grow with the highest CAGR throughout the forecast period.
- The hospital pharmacy drugs segment accounted for less than two-third share of the market in 2018.
- Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA.
Companies Mentioned
- Alvizia Healthcare Pvt. Ltd.
- Bayer AG
- F. Hoffmann-La Roche Ltd
- GlaxoSmithKline Plc
- Ipca Laboratories Ltd.
- Merck & Co. Inc
- Novartis AG
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd. (Ranbaxy Laboratories)
- Zydus Cadila
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...